55636-92-5

Usage

Uses

Used in Pharmaceutical Industry:
2-(hydroxyethyl)-7-(2-hydroxy-3-isopropylaminopropoxy)benzofuran is utilized as a drug and pharmaceutical intermediate for its potential to contribute to the creation of new medications. Its unique structure and functional groups make it a valuable target for medicinal chemistry, facilitating the design of novel therapeutic agents.
Used as a Vasodilator:
In the field of cardiovascular medicine, 2-(hydroxyethyl)-7-(2-hydroxy-3-isopropylaminopropoxy)benzofuran is considered for its potential as a vasodilator, which could help in the treatment of conditions associated with restricted blood flow.
Used as an Antiarrhythmic Agent:
2-(hydroxyethyl)-7-(2-hydroxy-3-isopropylaminopropoxy)benzofuran is also being explored for its possible role as an antiarrhythmic agent, which could be beneficial in managing heart rhythm disorders.
Used as an Antihypertensive Agent:
Furthermore, 2-(hydroxyethyl)-7-(2-hydroxy-3-isopropylaminopropoxy)benzofuran holds promise as an antihypertensive agent, suggesting its potential use in the treatment of high blood pressure.
Overall, the compound's multifaceted pharmacological profile positions it as a promising candidate for further research and development within the pharmaceutical and medical sectors.

InChI:InChI=1/C16H23NO4/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14/h4-7,10-11,13,17-19H,8-9H2,1-3H3

Upstream product

• 39552-01-7 befunolol 

Downstream Products

• 39552-01-7 befunolol 

Relevant academic research and scientific papers

Rabbit 3-hydroxyhexobarbital dehydrogenase is a NADPH-preferring reductase with broad substrate specificity for ketosteroids, prostaglandin D2, and other endogenous and xenobiotic carbonyl compounds

3-Hydroxyhexobarbital dehydrogenase (3HBD) catalyzes NAD(P) +-linked oxidation of 3-hydroxyhexobarbital into 3-oxohexobarbital. The enzyme has been thought to act as a dehydrogenase for xenobiotic alcohols and some hydroxysteroids, but its physiological function remains unknown. We have purified rabbit 3HBD, isolated its cDNA, and examined its specificity for coenzymes and substrates, reaction directionality and tissue distribution. 3HBD is a member (AKR1C29) of the aldo-keto reductase (AKR) superfamily, and exhibited high preference for NADP(H) over NAD(H) at a physiological pH of 7.4. In the NADPH-linked reduction, 3HBD showed broad substrate specificity for a variety of quinones, ketones and aldehydes, including 3-, 17- and 20-ketosteroids and prostaglandin D2, which were converted to 3α-, 17β- and 20α-hydroxysteroids and 9α,11β- prostaglandin F2, respectively. Especially, α-diketones (such as isatin and diacetyl) and lipid peroxidation-derived aldehydes (such as 4-oxo- and 4-hydroxy-2-nonenals) were excellent substrates showing low Km values (0.1-5.9 μM). In 3HBD-overexpressed cells, 3-oxohexobarbital and 5β-androstan-3α-ol-17-one were metabolized into 3-hydroxyhexobarbital and 5β-androstane-3α,17β-diol, respectively, but the reverse reactions did not proceed. The overexpression of the enzyme in the cells decreased the cytotoxicity of 4-oxo-2-nonenal. The mRNA for 3HBD was ubiquitously expressed in rabbit tissues. The results suggest that 3HBD is an NADPH-preferring reductase, and plays roles in the metabolisms of steroids, prostaglandin D2, carbohydrates and xenobiotics, as well as a defense system, protecting against reactive carbonyl compounds.

Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver

In this study, we compared the enzymatic reduction of 10 drugs with a ketone group by homogeneous carbonyl reductase, aldehyde reductase and three dihydrodiol dehydrogenases of human liver cytosol. At least one and in some cases all of the three dihydrodi